Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study

Osteoporosis International

Volumn 21, Issue 11, 2010, Pages 1911-1917

  Lamberg, A L ^a   Horvath Puho, E ^a   Christensen, S ^a   Sorensen H T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bisphosphonates; Case control study; Epidemiology; Osteoporosis; Pulmonary embolism; Venous thrombosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DENMARK; DISEASE ASSOCIATION; FEMALE; FRACTURE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGE DISTRIBUTION; AGED; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DENMARK; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; VENOUS THROMBOEMBOLISM;

EID: 78149411581     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1143-3     Document Type: Article

References (28)

1. JA Kanis N Burlet C Cooper PD Delmas JY Reginster F Borgstrom R Rizzoli 2008 European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 19 399 428 1:STN:280:DC%2BD1c3itFekuw%3D%3D 10.1007/s00198-008-0560-z 18266020
2. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley F Cosman P Lakatos PC Leung Z Man C Mautalen P Mesenbrink H Hu J Caminis K Tong T Rosario-Jansen J Krasnow TF Hue D Sellmeyer EF Eriksen SR Cummings 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 1:CAS:528:DC%2BD2sXltVSktLc%3D 10.1056/NEJMoa067312 17476007 (Pubitemid 46698462)
3. SR Cummings AV Schwartz DM Black 2007 Alendronate and atrial fibrillation N Engl J Med 356 1895 1896 1:CAS:528:DC%2BD2sXltVaisb0%3D 10.1056/NEJMc076132 17476024 (Pubitemid 46698498)
4. R Karam J Camm M McClung 2007 Yearly zoledronic acid in postmenopausal osteoporosis N Engl J Med 357 712 713 1:CAS:528:DC%2BD2sXptFKqtrY%3D 17703529
5. KW Lyles CS Colon-Emeric JS Magaziner JD Adachi CF Pieper C Mautalen L Hyldstrup C Recknor L Nordsletten KA Moore C Lavecchia J Zhang P Mesenbrink PK Hodgson K Abrams JJ Orloff Z Horowitz EF Eriksen S Boonen 2007 Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 1799 809 1:CAS:528:DC%2BD2sXht1Kit7nN 10.1056/NEJMoa074941 17878149 (Pubitemid 350044800)
6. HT Sorensen S Christensen F Mehnert L Pedersen RD Chapurlat SR Cummings JA Baron 2008 Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study BMJ 336 813 816 10.1136/bmj.39507.551644.BE 18334527 (Pubitemid 351548223)
7. FJ Fowkes JF Price FG Fowkes 2003 Incidence of diagnosed deep vein thrombosis in the general population: systematic review Eur J Vasc Endovasc Surg 25 1 5 1:STN:280:DC%2BD3s%2FhvV2jsQ%3D%3D 10.1053/ejvs.2002.1778 12525804 (Pubitemid 36527593)
8. JA Heit 2006 The epidemiology of venous thromboembolism in the community: implications for prevention and management J Thromb Thrombolysis 21 23 29 10.1007/s11239-006-5572-y 16475038 (Pubitemid 43231124)
9. SZ Goldhaber 2004 Pulmonary embolism Lancet 363 1295 1305 10.1016/S0140-6736(04)16004-2 15094276 (Pubitemid 38496494)
10. PA Kyrle S Eichinger 2005 Deep vein thrombosis Lancet 365 1163 1174 10.1016/S0140-6736(05)71880-8 15794972 (Pubitemid 40417567)
11. SR Cummings S Eckert KA Krueger D Grady TJ Powles JA Cauley L Norton T Nickelsen NH Bjarnason M Morrow ME Lippman D Black JE Glusman A Costa VC Jordan 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 2189 2197 1:CAS:528:DyaK1MXktFGitL0%3D 10.1001/jama.281.23. 2189 10376571 (Pubitemid 29275701)
12. IJ Diel R Bergner KA Grotz 2007 Adverse effects of bisphosphonates: current issues J Support Oncol 5 475 482 1:CAS:528:DC%2BD1cXhsVGgu7g%3D 18240669
13. S Adami N Zamberlan 1996 Adverse effects of bisphosphonates. A comparative review Drug Safety 14 158 170 1:CAS:528:DyaK28Xitlaqtbc%3D 10.2165/00002018-199614030-00003 8934578
14. Breart G, Cooper C, Meyer O, Speirs C, Deltour N, Reginster JY (2009) Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int. doi: 10.1007/s00198-009- 1050-7
15. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L (2009) Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. Osteoporos Int. doi: 10.1007.s00198-009-1091-y
16. L Frank 2000 Epidemiology. When an entire country is a cohort Science 287 2398 2399 1:CAS:528:DC%2BD3cXitlKgtbY%3D 10.1126/science.287.5462.2398 10766613 (Pubitemid 30185417)
17. RJ Glynn B Rosner 2005 Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism Am J Epidemiol 162 975 982 10.1093/aje/kwi309 16207808 (Pubitemid 41619468)
18. S Wacholder JK McLaughlin DT Silverman JS Mandel 1992 Selection of controls in case-control studies. I. Principles Am J Epidemiol 135 1019 1028 1:STN:280:DyaK383otVOqtQ%3D%3D 1595688
19. S Suissa 2008 Immeasurable time bias in observational studies of drug effects on mortality Am J Epidemiol 168 329 335 10.1093/aje/kwn135 18515793 (Pubitemid 352019783)
20. MM Samama 2000 An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study Arch Intern Med 160 3415 3420 1:STN:280:DC%2BD3M%2FnvVeltA%3D%3D 10.1001/archinte.160.22.3415 11112234
21. S Hagg O Spigset 2002 Antipsychotic-induced venous thromboembolism: a review of the evidence CNS Drugs 16 765 776 10.2165/00023210-200216110-00005 12383032
22. GL Zornberg H Jick 2000 Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study Lancet 356 1219 1223 1:CAS:528:DC%2BD3cXot1ahu74%3D 10.1016/S0140-6736(00)02784-7 11072939
23. Rothman KJ, Greenland S (2008) Modern epidemiology (third edition). Philadelphia, PA: Lippencott, pp 435-457
24. HT Sorensen TL Lash KJ Rothman 2006 Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies Hepatology 44 1075 1082 10.1002/hep.21404 17058242 (Pubitemid 44748358)
25. SK Thygesen SF Christiansen TL Lash HT Sørensen 2009 Predictive value of coding of diagnoses in the Charlson Index in the Danish National Registry of Patients Pharmacoepidemiol Drug Saf 18 189
26. WD Kniffin Jr JA Baron J Barrett JD Birkmeyer FA Anderson Jr 1994 The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly Arch Intern Med 154 861 866 10.1001/archinte.154.8.861 8154949 (Pubitemid 24135768)
27. S Schulman P Lindmarker 2000 Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial N Engl J Med 342 1953 1958 1:STN:280:DC%2BD3czit1arsQ%3D%3D 10.1056/NEJM200006293422604 10874063 (Pubitemid 30419090)
28. J Hirsh TE Warkentin SG Shaughnessy SS Anand JL Halperin R Raschke C Granger EM Ohman JE Dalen 2001 Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Chest 119 64S 94S 1:CAS:528:DC%2BD3MXhtlamsrg%3D 10.1378/chest.119.1-suppl.64S 11157643